Core Insights - The Allstate Corporation (ALL) is set to release its third-quarter 2025 results on November 5, with earnings estimated at $8.20 per share, more than double the prior-year quarter's figure [1][5] - The revenue consensus estimate stands at $17.4 billion, reflecting a 5.9% growth from the same quarter last year [2] Earnings Estimates and Revisions - The third-quarter earnings estimate has seen four upward revisions in the last 30 days, with no downward movements [2] - Allstate has an Earnings ESP of 0.00% and currently holds a Zacks Rank of 3 (Hold) [4] Historical Performance - Allstate has consistently beaten earnings estimates in the past four quarters, with an average surprise of 57.67% [3] Revenue Drivers - Revenue growth is expected to be driven by improved net premiums earned due to higher policies in force, with net earned premiums projected to grow 8.3% year over year to $15.5 billion [5][6] - The Property-Liability segment is anticipated to benefit from higher earned premiums, with a consensus estimate of $14.8 billion, indicating a 7.8% increase from the previous year [7] Investment Income - Net investment income is expected to rise to $832 million, marking a 6.3% improvement from the prior-year quarter [6] Underwriting Challenges - Catastrophe losses are projected to impact underwriting results, with management forecasting pre-tax catastrophe losses of $558 million for the quarter [8] - Claims expenses are expected to increase by 2.7% year over year to $10.7 billion, which may pressure overall margins [10] Segment Performance - The Protection Services segment is expected to see revenue growth, with estimates pegged at $899 million, reflecting an 8.1% increase from the prior-year quarter [9]

Core Insights - Wheaton Precious Metals (WPM) is set to report its third-quarter 2025 results on November 6, with sales estimated at $470.4 million, reflecting a 52.5% year-over-year growth, and earnings per share (EPS) projected at 59 cents, indicating a 73.5% increase from the previous year [1][5][6] Financial Performance - The Zacks Consensus Estimate for WPM's third-quarter sales is $470.4 million, which represents a 52.5% increase compared to the same quarter last year [1][5] - The consensus estimate for earnings is 59 cents per share, showing a year-over-year growth of 73.5% [1][5] - Earnings estimates have decreased by 1.7% over the past 60 days [1] Earnings Surprise History - WPM has outperformed the consensus estimate in two of the last four quarters, with an average surprise of 4.7% [3][4] Production Outlook - WPM anticipates an attributable production of 600,000-670,000 gold equivalent ounces (GEOs) for 2025, indicating a 10% year-over-year increase [7] - The third-quarter production is projected at 162,298 GEOs, reflecting a 13.7% year-over-year increase, including 94,165 ounces of gold, which is an 8.5% increase [8][10] Sales Projections - Total gold sales for the third quarter are expected to reach $275 million, a 46% year-over-year rise, contributing 60.3% to total sales [11] - Silver sales volume is projected at 5.52 million ounces, leading to $176 million in sales, a 52.9% increase year-over-year [12] Price Performance - WPM's stock has increased by 51% over the past year, significantly outperforming the industry average growth of 19.3% [14]

Core Viewpoint - Premier, Inc. reported a decline in revenue and earnings for the quarter ended September 2025, indicating potential challenges in financial performance despite some positive surprises against estimates [1][2]. Financial Performance Summary - Revenue for the quarter was $240 million, down 3.3% year-over-year, but exceeded the Zacks Consensus Estimate of $239.23 million by +0.32% [1]. - Earnings per share (EPS) were $0.30, a decrease from $0.34 in the same quarter last year, but surpassed the consensus estimate of $0.28 by +7.14% [1]. - The stock has returned +1.2% over the past month, underperforming the Zacks S&P 500 composite's +2.1% change [3]. Key Metrics Overview - Net Revenue from Supply Chain Services - Software licenses and other services was $19.68 million, slightly below the average estimate of $19.75 million [4]. - Net Revenue from Performance Services was $87.92 million, down 9.1% year-over-year, and below the average estimate of $89.51 million [4]. - Total Net Revenue from Supply Chain Services was $152.09 million, exceeding the average estimate of $149.72 million with a year-over-year change of +0.5% [4]. - Net administrative fees from Supply Chain Services were $132.4 million, slightly above the average estimate of $129.97 million, with a year-over-year change of -0.2% [4]. - Adjusted EBITDA for Performance Services was $10.62 million, below the average estimate of $15.01 million [4]. - Adjusted EBITDA for Supply Chain Services was $76.17 million, exceeding the average estimate of $72.28 million [4].

Core Viewpoint - Bolt Biotherapeutics, Inc. (BOLT) is anticipated to report a year-over-year increase in earnings despite lower revenues for the quarter ending September 2025, with actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The consensus estimate indicates a quarterly loss of $5.07 per share, reflecting a year-over-year change of +36.6%, while revenues are projected to be $0.77 million, down 32.5% from the previous year [3]. - The consensus EPS estimate has been revised 0.83% lower in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows that the Most Accurate Estimate for Bolt Biotherapeutics is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.33%, suggesting a bullish outlook on earnings prospects [12]. - The stock currently holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Bolt Biotherapeutics was expected to post a loss of $6.4 per share but actually reported a loss of -$4.46, achieving a surprise of +30.31% [13]. - Over the past four quarters, the company has surpassed consensus EPS estimates two times [14]. Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Protagonist Therapeutics (PTGX) is expected to report a loss of $0.59 per share for the same quarter, with a year-over-year change of -9.3% and projected revenues of $10 million, up 113.7% from the previous year [18][19]. - Protagonist Therapeutics has a higher Most Accurate Estimate leading to an Earnings ESP of +29.92%, suggesting a strong likelihood of beating the consensus EPS estimate [19][20].

Core Viewpoint - The market anticipates that Sky Harbour Group Corporation (SKYH) will report flat earnings compared to the previous year, with revenues expected to increase significantly [1][3]. Earnings Expectations - The consensus EPS estimate for Sky Harbour Group is a loss of $0.10 per share, unchanged from the year-ago quarter, while revenues are projected to be $8.63 million, reflecting a 110.5% increase year-over-year [3]. - The earnings report could lead to a stock price increase if actual results exceed expectations, but a miss could result in a decline [2]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 25%, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4][12]. - The Most Accurate Estimate for Sky Harbour Group is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -10.00% [12]. Historical Performance - In the last reported quarter, Sky Harbour Group was expected to post a loss of $0.12 per share but actually reported a loss of $0.10, achieving a surprise of +16.67% [13]. - The company has beaten consensus EPS estimates three times over the last four quarters [14]. Comparative Analysis - Rocket Lab Corporation (RKLB), another player in the aerospace-defense equipment industry, is expected to report a loss of $0.05 per share, with revenues projected at $149.82 million, a 42.9% increase year-over-year [18][19]. - Rocket Lab's consensus EPS estimate has remained unchanged, but a higher Most Accurate Estimate gives it an Earnings ESP of +25.00%, indicating a likely beat of the consensus EPS estimate [19][20].

Core Viewpoint - Wall Street anticipates flat earnings for SKYX Platforms Corp. with a projected quarterly loss of $0.08 per share and revenues of $23.2 million, reflecting a 4.7% increase year-over-year [1][3]. Earnings Expectations - The consensus EPS estimate has been revised down by 33.33% over the last 30 days, indicating a reassessment by analysts [4]. - A positive or negative Earnings ESP reading can indicate the likely deviation of actual earnings from the consensus estimate, with a positive reading being a strong predictor of an earnings beat [9][10]. Earnings Surprise Prediction - The Most Accurate Estimate for SKYX is the same as the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, making it challenging to predict an earnings beat [12]. - SKYX currently holds a Zacks Rank of 3, which does not strongly indicate an earnings beat [12]. Historical Performance - In the last reported quarter, SKYX matched the expected loss of $0.08 per share, resulting in no surprise [13]. - Over the past four quarters, SKYX has beaten consensus EPS estimates twice [14]. Industry Comparison - Bitdeer Technologies Group (BTDR) is expected to report a loss of $0.22 per share, a year-over-year change of +37.1%, with revenues projected at $161.14 million, up 159.8% from the previous year [18][19]. - The consensus EPS estimate for Bitdeer has been revised 40% higher in the last 30 days, with a positive Earnings ESP of +27.27%, suggesting a likely earnings beat [19][20].

分组1 - Vital Farms reported quarterly earnings of $0.36 per share, exceeding the Zacks Consensus Estimate of $0.30 per share, and showing an increase from $0.16 per share a year ago, representing an earnings surprise of +20.00% [1] - The company achieved revenues of $198.94 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 3.79% and increasing from $145 million year-over-year [2] - Vital Farms has outperformed consensus EPS estimates in all four of the last quarters and has topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has underperformed the market, losing about 14.6% since the beginning of the year, while the S&P 500 gained 16.5% [3] - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at $0.37 for the coming quarter and $1.38 for the current fiscal year [7] - The Zacks Industry Rank for Food - Miscellaneous is currently in the bottom 33% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Core Insights - Freshpet Inc. reported third-quarter earnings significantly above Wall Street expectations, with shares rising over 9% in intra-day trading [1] - The company achieved adjusted earnings of $1.86 per share, exceeding analyst estimates of $0.43 [1] - Revenue increased by 14% year-over-year to $288.8 million, surpassing the consensus forecast of $284.22 million [1] Financial Performance - Freshpet achieved positive free cash flow for the first time during the quarter and anticipates remaining free cash flow positive for the full fiscal year 2025, one year earlier than previously expected [2] - Adjusted EBITDA rose to $54.6 million from $43.5 million in the same quarter last year [2] Guidance Update - The company updated its full-year 2025 guidance, projecting net sales growth of approximately 13%, slightly down from the prior range of 13% to 16% [3] - Adjusted EBITDA outlook was narrowed to between $190 million and $195 million from the previous range of $190 million to $210 million [3] - Capital expenditure guidance was reduced to about $140 million from $175 million [3]

Core Insights - Emerson Electric Co. is a global technology and engineering company with a market cap of $78.6 billion, providing solutions across various sectors including industrial, commercial, and residential markets [1] Stock Performance - The stock has underperformed the broader market in 2025, with a 12.6% increase, but has outperformed over the past year with a 28% rise compared to the S&P 500 Index's 16.3% YTD gains and 17.7% returns over the past year [2] - Compared to the Industrial Select Sector SPDR Fund (XLI), EMR has lagged behind its 17.7% gains in 2025 but outperformed XLI's 14.5% returns over the past year [3] Financial Results - Following the release of mixed Q3 results, Emerson's stock dropped 4.7%, primarily due to net sales of $4.6 billion missing expectations by 60 basis points, although this figure represented a nearly 4% year-over-year increase [4] - The company reported strong profitability and cash flows, with adjusted EPS increasing 6.3% year-over-year to $1.52, surpassing consensus estimates by 66 basis points, and generated free cash flows of $970 million during the quarter [4] Future Outlook - For the full fiscal 2025, analysts expect an adjusted EPS of $6, reflecting a 9.3% year-over-year increase, with a solid earnings surprise history as the company has exceeded bottom-line estimates in the past four quarters [5] - Among 24 analysts covering EMR, the consensus rating is a "Moderate Buy," consisting of 15 "Strong Buys," one "Moderate Buy," seven "Holds," and one "Moderate Sell" [5] - A month ago, the outlook was slightly more optimistic with 16 analysts recommending "Strong Buy" [6] Analyst Ratings - On October 15, JP Morgan analyst Stephen Tusa maintained a "Neutral" rating on EMR and raised the price target from $135 to $151 [7]

Core Insights - Rigel Pharmaceuticals (RIGL) is set to report its third-quarter 2025 results on November 4, with revenue expectations at $61.6 million and earnings at 93 cents per share [1][6] Group 1: Revenue Drivers - The primary revenue sources for Rigel include sales from marketed products and contract revenues from collaborations [2] - The significant revenue growth in Q3 is anticipated to be driven by strong demand for Tavalisse, which treats chronic immune thrombocytopenia (ITP) [2][6] - Sales from other marketed products, Rezlidhia (olutasidenib) and Gavreto (pralsetinib), are also expected to contribute positively to Rigel's revenue in the upcoming quarter [3][6] Group 2: Stock Performance - Year-to-date, Rigel's shares have increased by 88%, significantly outperforming the industry average rise of 7.3% [3] Group 3: Pipeline Developments - Rigel is advancing its pipeline with R289, a dual IRAK1 and IRAK4 inhibitor, currently in early-stage studies for lower-risk myelodysplastic syndrome (MDS) [4] - The company is also exploring additional uses for Rezlidhia beyond its current approval for relapsed or refractory IDH1-mutated acute myeloid leukemia (AML) [7] Group 4: Earnings Surprise History - Rigel has a strong history of earnings surprises, having exceeded earnings expectations in the last four quarters with an average surprise of 1,840.49% [8] Group 5: Earnings Prediction Model - The current model does not predict a definitive earnings beat for Rigel, as the Earnings ESP stands at 0.00% with both the Most Accurate Estimate and the Zacks Consensus Estimate at 93 cents per share [9][10]